<?xml version="1.0" encoding="UTF-8"?>
<collection>
<dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:invenio="http://invenio-software.org/elements/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:identifier>doi:10.3389/fimmu.2023.1277793</dc:identifier><dc:language>deu</dc:language><dc:creator>Ayerdi, Oskar</dc:creator><dc:creator>Benito, Rafael</dc:creator><dc:creator>Ortega, Diego</dc:creator><dc:creator>Aguilera, Antonio</dc:creator><dc:creator>Montiel, Natalia</dc:creator><dc:creator>Pintos, Ilduara</dc:creator><dc:creator>Díaz de Santiago, Alberto</dc:creator><dc:creator>Baza, Begoña</dc:creator><dc:creator>Soriano, Vicente</dc:creator><dc:creator>de Mendoza, Carmen</dc:creator><dc:title>HTLV infection in persons with sexually transmitted diseases in Spain</dc:title><dc:identifier>ART-2023-137164</dc:identifier><dc:description>Background: HTLV-1 infection is a neglected disease, despite estimates of 10 million people infected worldwide and producing life-threatening illnesses in 10% of carriers. Sexual transmission is the main route of contagion. However, HTLV-1 is not listed among sexually transmitted infections (STIs).

Methods: Serum from all consecutive individuals who had attended six STI clinics across Spain during the last 12 months were tested for HTLV antibodies using a commercial enzyme immunoassay (EIA). Reactive samples were confirmed by immunoblot.

Results: A total of 2,524 samples were examined. The majority (1,936; 76.7%) belonged to men, of whom 676 (34.9%) were men who have sex with men (MSM) receiving HIV pre-exposure prophylaxis. Although native Spaniards predominated (1,470; 58.2%), up to 593 (23.5%) came from Latin America and 139 (5.5%) were African. A total of 26 individuals were initially EIA reactive and immunoblot confirmed 5 as HTLV-1 and 7 as HTLV-2. All but one HTLV-1+ case came from Latin America. Three were men and two were women. Among Latin Americans, the HTLV-1 seroprevalence was 0.67%. In contrast, all seven HTLV-2+ were native Spaniards and former injection drug users, and all but one were HIV+.

Conclusion: The rate of HTLV infection among individuals with STIs in Spain is 0.5%, which is greater than in the general population. These results support the introduction of universal HTLV screening in persons who attend clinics for STIs.</dc:description><dc:date>2023</dc:date><dc:source>http://zaguan.unizar.es/record/131799</dc:source><dc:doi>10.3389/fimmu.2023.1277793</dc:doi><dc:identifier>http://zaguan.unizar.es/record/131799</dc:identifier><dc:identifier>oai:zaguan.unizar.es:131799</dc:identifier><dc:relation>info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI21-1717</dc:relation><dc:identifier.citation>Frontiers in Immunology 14 (2023), 1277793 [6 pp.]</dc:identifier.citation><dc:rights>by</dc:rights><dc:rights>http://creativecommons.org/licenses/by/3.0/es/</dc:rights><dc:rights>info:eu-repo/semantics/openAccess</dc:rights></dc:dc>

</collection>